Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study

被引:10
作者
Kjellander, Christian [1 ,2 ,3 ]
Bjorkholm, Magnus [1 ,2 ]
Kallman, Owe [4 ,5 ]
Giske, Christian G. [4 ,5 ]
Weibull, Caroline E. [6 ]
Love, Thorvardur J. [7 ,8 ,10 ,11 ]
Landgren, Ola [9 ]
Kristinsson, Sigurdur Y. [1 ,2 ,10 ,11 ]
机构
[1] Karolinska Univ Hosp Solna, Dept Med, Div Hematol, Stockholm, Sweden
[2] Karolinska Inst, Stockholm, Sweden
[3] Karolinska Univ Sjukhuset Solna, Hematol Ctr, S-17176 Stockholm, Sweden
[4] Karolinska Univ Hosp, Clin Microbiol, Stockholm, Sweden
[5] Karolinska Inst, Dept Lab Med, Stockholm, Sweden
[6] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[7] Landspitali Univ Hosp, Ctr Rheumatol Res, Reykjavik, Iceland
[8] Univ Iceland, Reykjavik, Iceland
[9] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA
[10] Univ Iceland, Fac Med, Reykjavik, Iceland
[11] Landspitali Univ Hosp, Reykjavik, Iceland
关键词
Chronic lymphocytic leukemia; Infections; Prognosis; Bloodstream infections; Splenectomy; TRIMETHOPRIM-SULFAMETHOXAZOLE; HEMATOLOGICAL MALIGNANCIES; INITIAL THERAPY; FLUDARABINE; BACTEREMIA; RITUXIMAB; CANCER; CYCLOPHOSPHAMIDE; ALEMTUZUMAB; RESISTANCE;
D O I
10.1007/s00277-016-2643-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Infectious complications in chronic lymphocytic leukemia (CLL) represent a major cause of morbidity and mortality. The aim of the study was to investigate temporal trends in bloodstream infections (BSIs) among patients with CLL. Individuals with blood cultures were linked to Swedish Cancer Registry and divided into three time periods (1988-1993, 1994-1999, and 2000-2006) according to year of CLL diagnosis. CLL patients (n = 275) with 1092 blood culture episodes were identified and linked to the nationwide Cause of Death Registry and Swedish Patient Registry (to retrieve information on splenectomies). The most common causes of BSI among CLL patients were Escherichia coli (11/43, 15/78, and 9/33), Streptococcus pneumoniae (7/43, 13/78, and 6/33), Pseudomonas aeruginosa (2/43, 8/78, and 3/33), Staphylococcus aureus (1/43, 6/78, and 6/33), and Viridans streptococci (5/43, 6/78, and 2/33). Coagulase-negative staphylococci was the most frequent microorganism found in blood cultures (22/70, 23/106, and 5/41, respectively) but is a frequent contaminant. Based on the largest study to date on BSI in CLL patients, we found a stable proportion of Gram-positive to Gram-negative bacteria and no temporal change of distribution was observed for BSIs 1988-2006.
引用
收藏
页码:871 / 879
页数:9
相关论文
共 37 条
  • [1] Infections in patients with chronic lymphocytic leukemia treated with fludarabine
    Anaissie, EJ
    Kontoyiannis, DP
    O'Brien, S
    Kantarjian, H
    Robertson, L
    Lerner, S
    Keating, MJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (07) : 559 - 566
  • [2] The completeness of the Swedish Cancer Register - a sample survey for year 1998
    Barlow, Lotti
    Westergren, Kerstin
    Holmberg, Lars
    Talback, Mats
    [J]. ACTA ONCOLOGICA, 2009, 48 (01) : 27 - 33
  • [3] Alemtuzumab in the treatment of chronic lymphocytic lymphoma
    Boyd, Kevin
    Dearden, Claire E.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (04) : 525 - 533
  • [4] BACTEREMIA AND CANDIDEMIA IN HEMATOLOGICAL MALIGNANCIES - MICROBIOLOGICAL FINDINGS AND ANTIBIOTIC SUSCEPTIBILITIES
    BRUUN, B
    BANGSBORG, J
    HOVGAARD, D
    SKINHOJ, P
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1988, 20 (05) : 503 - 509
  • [5] Cusack JC, 1997, J AM COLL SURGEONS, V185, P237
  • [6] Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future
    Desai, Anjali Varma
    El-Bakkar, Hassan
    Abdul-Hay, Maher
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (06) : 314 - 322
  • [7] The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia
    Francis, Sebastian
    Karanth, Mamatha
    Pratt, Guy
    Starczynski, Jane
    Hooper, Laura
    Fegan, Chris
    Pepper, Chris
    Valcarcel, David
    Milligan, Donald W.
    Delgado, Julio
    [J]. CANCER, 2006, 107 (05) : 1023 - 1033
  • [8] PROSPECTIVE CONTROLLED INVESTIGATION OF PROPHYLACTIC TRIMETHOPRIM-SULFAMETHOXAZOLE IN HOSPITALIZED GRANULOCYTOPENIC PATIENTS
    GURWITH, MJ
    BRUNTON, JL
    LANK, BA
    HARDING, GKM
    RONALD, AR
    [J]. AMERICAN JOURNAL OF MEDICINE, 1979, 66 (02) : 248 - 256
  • [9] Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network
    Hainsworth, JD
    Litchy, S
    Barton, JH
    Houston, GA
    Hermann, RC
    Bradof, JE
    Greco, FA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) : 1746 - 1751
  • [10] Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
    Hallek, M.
    Fischer, K.
    Fingerle-Rowson, G.
    Fink, A. M.
    Busch, R.
    Mayer, J.
    Hensel, M.
    Hopfinger, G.
    Hess, G.
    von Gruenhagen, U.
    Bergmann, M.
    Catalano, J.
    Zinzani, P. L.
    Caligaris-Cappio, F.
    Seymour, J. F.
    Berrebi, A.
    Jaeger, U.
    Cazin, B.
    Trneny, M.
    Westermann, A.
    Wendtner, C. M.
    Eichhorst, B. F.
    Staib, P.
    Buehler, A.
    Winkler, D.
    Zenz, T.
    Boettcher, S.
    Ritgen, M.
    Mendila, M.
    Kneba, M.
    Doehner, H.
    Stilgenbauer, S.
    [J]. LANCET, 2010, 376 (9747) : 1164 - 1174